Sugi Predict

Sugi Predict / Targets / HACL2

HACL2

2-hydroxyacyl-CoA lyase 2 · A1L0T0 · HACL2 on Sugi Atlas →

21 patent compounds predicted against HACL2, 17 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL21943538 SCHEMBL21943538 0.59 1/20
SCHEMBL21943762 SCHEMBL21943762 0.57 1/20
SCHEMBL21944043 SCHEMBL21944043 0.55 1/20
SCHEMBL21943004 SCHEMBL21943004 0.55 1/20
SCHEMBL21942995 SCHEMBL21942995 0.53 1/20
SCHEMBL21943411 SCHEMBL21943411 0.53 1/20
SCHEMBL14042267 SCHEMBL14042267 0.52 1/20
SCHEMBL21943429 SCHEMBL21943429 0.52 1/20
SCHEMBL22066328 SCHEMBL22066328 0.51 1/20
SCHEMBL21943540 SCHEMBL21943540 0.49 1/20
SCHEMBL21943537 SCHEMBL21943537 0.45 1/20
SCHEMBL24016281 SCHEMBL24016281 0.44 1/20
SCHEMBL24532074 SCHEMBL24532074 0.42 1/20
SCHEMBL1454562 SCHEMBL1454562 0.42 1/20
SCHEMBL17612956 SCHEMBL17612956 0.42 1/20
SCHEMBL12399198 SCHEMBL12399198 0.42 1/20
SCHEMBL29911712 SCHEMBL29911712 0.40 1/20

Clinical trials — most relevant to HACL2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Bezafibrate Trial in CPT2 Deficiency PHASE3UNKNOWN
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency PHASE2/PHASE3COMPLETED
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity PHASE2/PHASE3RECRUITING
Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency PHASE3COMPLETED
Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia PHASE3COMPLETED
Cholic Acid for Hepatic Steatosis in Lipodystrophy PHASE2COMPLETED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia PHASE2COMPLETED
Folate Rechallenge PHASE2COMPLETED
Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris PHASE1/PHASE2UNKNOWN
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease PHASE1COMPLETED
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease EARLY_PHASE1COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
The Roles of SAH Gene Family in Athrogenic Dyslipidemia in Postmenopausal Women nanUNKNOWN
11C-Acetate PET/CT Non-FDG-Avid Tumors nanUNKNOWN
Role of Dairy Products in Weight Maintenance nanCOMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity nanCOMPLETED
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes nanRECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Androgens and NAFLD Longitudinal Cohort Study nanRECRUITING
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease nanUNKNOWN
Stone Disease in Children and Their Families nanCOMPLETED
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing nanCOMPLETED
Lipodystrophy Connect Patient Registry nanCOMPLETED
Returning Genetic Results on Arsenic Susceptibility nanCOMPLETED
Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a HACL2 binder may also engage these)

ProteinNameSimilarity
A6QQT9 — 1.000 A6QQT9 →
Q8BU33 — 1.000 Q8BU33 →
Q6NV04 — 0.987 Q6NV04 →
Q8CHM7 — 0.980 Q8CHM7 →
O61856 — 0.980 O61856 →
A2YQ76 — 0.978 A2YQ76 →
Q6DDK5 — 0.977 Q6DDK5 →
Q0D3D2 — 0.976 Q0D3D2 →
Q0JMH0 — 0.976 Q0JMH0 →
Q9LF46 — 0.975 Q9LF46 →
A0A7J6EK66 — 0.975 A0A7J6EK66 →
A2XFI3 — 0.975 A2XFI3 →
P28516 — 0.974 P28516 →
Q9QXE0 — 0.973 Q9QXE0 →
P51845 — 0.973 P51845 →
Q10MW3 — 0.973 Q10MW3 →
P51850 — 0.973 P51850 →
Q5RAP5 — 0.973 Q5RAP5 →
Q38854 — 0.972 Q38854 →
P51851 — 0.972 P51851 →
Q8N2H3 — 0.972 Q8N2H3 →
Q9Y7M1 — 0.972 Q9Y7M1 →
A2Y5L9 — 0.971 A2Y5L9 →
Q6YU51 — 0.971 Q6YU51 →
Q9FFT4 — 0.970 Q9FFT4 →
Q9UJ83 — 0.970 Q9UJ83 →
P33287 — 0.970 P33287 →
Q67NB6 — 0.970 Q67NB6 →
O22567 — 0.969 O22567 →
Q0DHF6 — 0.969 Q0DHF6 →